Mixed results for bone marrow–derived cell therapy for ischemic heart disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed.

1. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.European heart journal · 2017
   Trial
2. Microstructural impact of ischemia and bone marrow-derived cell therapy revealed with diffusion tensor magnetic resonance imaging tractography of the heart in vivo.Circulation · 2014
   Trial
3. Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.European journal of medical research · 2022
   Review
4. Multiplexed targeting of miRNA-210 in stem cell-derived extracellular vesicles promotes selective regeneration in ischemic hearts.Experimental & molecular medicine · 2021
   Article
5. The Roles of Nanoparticles in Stem Cell-Based Therapy for Cardiovascular Disease.Frontiers in bioengineering and biotechnology · 2020
   Review
6. Mechanisms of stem cell based cardiac repair-gap junctional signaling promotes the cardiac lineage specification of mesenchymal stem cells.Scientific reports · 2017
   Article
7. Cardiac Strain in a Swine Model of Regional Hibernating Myocardium: Effects of CoQ10 on Contractile Reserve Following Bypass Surgery.Journal of cardiovascular translational research · 2016
   Article
8. Stem cell therapy for heart failure: Ensuring regenerative proficiency.Trends in cardiovascular medicine · 2016
   Review
9. Nanoparticles-Assisted Stem Cell Therapy for Ischemic Heart Disease.Stem cells international · 2016
   Review
10. Comparative Efficacy of Intracoronary Allogeneic Mesenchymal Stem Cells and Cardiosphere-Derived Cells in Swine with Hibernating Myocardium.Circulation research · 2015
    Article
11. Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement.Journal of the American College of Cardiology · 2014
    Review
12. Controlling the structural and functional anisotropy of engineered cardiac tissues.Biofabrication · 2014
    Article
13. Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells.Mayo Clinic proceedings · 2014
    Review
14. Cell therapy for cardiac repair--lessons from clinical trials.Nature reviews. Cardiology · 2014
    Review
15. Spatial control of adult stem cell fate using nanotopographic cues.Biomaterials · 2014
    Article
16. The advancing field of cell-based therapy: insights and lessons from clinical trials.Journal of the American Heart Association · 2013
    Review
17. Cardiac stem cell therapy and the promise of heart regeneration.Cell stem cell · 2013
    Article
18. Current status of cell-based therapy for heart failure.Current heart failure reports · 2013
    Review
19. Bone marrow tinctures for cardiovascular disease: lost in translation.Circulation · 2013
    Article
20. Bone marrow-derived cell therapy after myocardial infarction.JAMA · 2013
    Article

Corrections and comments

• Commented on by
  Bone marrow-derived cell therapy after myocardial infarction.2013
• Commented on by
  Bone marrow-derived cell therapy after myocardial infarction--reply.2013
• Comment on
  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.2012
• Comment on
  Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as